No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
No Data
Analyst Expectations For Celldex Therapeutics's Future
HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target
H.C. Wainwright Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $80
Express News | Celldex Therapeutics Inc -Embarq-Csu1 and Embarq-Csu 2 Will Enroll More Than 1800 Patients Suffering From Csu
Express News | Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients With Chronic Spontaneous Urticaria
Celldex Therapeutics(CLDX.US) Officer Sells US$608.31K in Common Stock